C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 4.28 USD -2.28% Market Closed
Market Cap: 302.1m USD
Have any thoughts about
C4 Therapeutics Inc?
Write Note

C4 Therapeutics Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

C4 Therapeutics Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
C4 Therapeutics Inc
NASDAQ:CCCC
Net Income (Common)
-$132.5m
CAGR 3-Years
-26%
CAGR 5-Years
-41%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

C4 Therapeutics Inc
Glance View

Market Cap
302m USD
Industry
Biotechnology

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

CCCC Intrinsic Value
1.92 USD
Overvaluation 55%
Intrinsic Value
Price

See Also

What is C4 Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-132.5m USD

Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Net Income (Common) amounts to -132.5m USD.

What is C4 Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-41%

Over the last year, the Net Income (Common) growth was -3%. The average annual Net Income (Common) growth rates for C4 Therapeutics Inc have been -26% over the past three years , -41% over the past five years .

Back to Top